Related Experiment Video
Updated: Aug 5, 2026
09:07
Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats
Published on: February 23, 2015
Aging, Alzheimer's disease, and estrogen therapy
1Department of Geriatrics, University Hospitals of Geneva, University of Geneva, Medical School, Switzerland.
Experimental Gerontology
|February 10, 1999
Summary
Estrogen therapy may lower Alzheimer's Disease (AD) risk in post-menopausal women. However, more large, randomized trials are needed to confirm these findings before recommending estrogen for AD prevention.
Area of Science:
- Neuroscience
- Endocrinology
- Gerontology
Background:
- Retrospective studies and in vitro/in vivo experiments suggest a potential link between estrogen use and reduced Alzheimer's Disease (AD) risk.
- Observational data indicate that long-term estrogen therapy might be associated with a lower incidence of AD in post-menopausal women.
Purpose of the Study:
- To evaluate the potential of estrogen therapy in preventing Alzheimer's Disease (AD).
- To determine if existing evidence warrants recommending estrogen for AD prevention in post-menopausal women.
Main Methods:
- Review of experimental studies (in vivo and in vitro).
- Analysis of retrospective studies involving post-menopausal women.
- Identification of the need for large, randomized, placebo-controlled trials.
Main Results:
- Preliminary evidence from various study types suggests a possible protective effect of estrogen against AD.
- Retrospective data indicate a potential reduction in AD risk with prolonged estrogen use.
Conclusions:
- Current evidence, primarily from retrospective studies, is insufficient to recommend estrogen for Alzheimer's Disease (AD) prevention.
- Large-scale, randomized, placebo-controlled trials are essential to establish the efficacy and safety of estrogen therapy for AD prevention.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...